[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100613176":3},{"organization":4,"outcomesModule":7,"designInfo":36,"detailedDescription":19,"studyPopulation":39,"armGroups":19,"interventions":40,"overallOfficials":19,"centralContacts":45,"locations":51,"responsibleParty":66,"collaborators":19,"id":68,"slug":19,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":19,"eligibilityCriteria":73,"healthyVolunteers":69,"sex":74,"minAge":75,"maxAge":19,"enrollmentInfo":76,"targetDuration":19,"studyType":79,"phases":19,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":54,"whyStopped":19,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"Boryung Pharmaceutical Co., Ltd","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":19},[9],{"measure":10,"description":11,"timeFrame":12},"Progression-free survival (PFS)","Progression-free survival (PFS) by treatment pattern","up to 24 months",[14,17,20,22,24,26,29,33],{"measure":15,"description":16,"timeFrame":12},"Overall Survival (OS)","Overall Survival (OS) by treatment pattern",{"measure":18,"description":19,"timeFrame":12},"Dosage period for each treatment pattern",null,{"measure":21,"description":19,"timeFrame":12},"Objective Response Rate (ORR)",{"measure":23,"description":19,"timeFrame":12},"Types of Secondary palliative chemotherapy",{"measure":25,"description":19,"timeFrame":12},"Types of Third palliative chemotherapy",{"measure":27,"description":28,"timeFrame":12},"Conversion rate","Conversion rate to resectable group by treatment pattern",{"measure":30,"description":31,"timeFrame":32},"Quality of Life Assessment","The FACT-C (Functional Assessment of Cancer Therapy-Colorectal) questionnaire uses a 5-point Likert-type scale. The responses generally range from 0 (Not at all) to 4 (Very much).","up to 12 months",{"measure":34,"description":35,"timeFrame":12},"Eastern Cooperative Oncology Group Performance Status(ECOG PS) Assessment","The ECOG PS uses a scale from 0 to 5, where a score of 5 specifically means the patient is deceased. The score of 0 indicates the best performance status (fully active), while 4 indicates the worst performance status for a living patient (completely disabled\u002Fbedridden).",{"allocation":19,"interventionModel":19,"interventionModelDescription":19,"primaryPurpose":19,"observationalModel":37,"timePerspective":38,"maskingInfo":19},"COHORT","PROSPECTIVE","Patients with metastatic colorectal cancer (colon and rectal cancer) who have failed first-line palliative chemotherapy",[41],{"type":42,"name":43,"description":44,"armGroupLabels":19,"otherNames":19},"DRUG","Second and later-line palliative chemotherapy","As this is a non-interventional study designed to collect data as part of routine clinical practice, the selection and dosage of medication, treatment period, and whether or not to change it are all based on the clinician's judgment",[46],{"name":47,"role":48,"phone":49,"phoneExt":19,"email":50},"Shinyoung Oh","CONTACT","027088000","syoh@boryung.co.kr",[52],{"facility":53,"status":54,"city":55,"state":19,"zip":19,"country":56,"countryCode":19,"cosmosGeoPoint":57,"geoPoint":62,"contacts":63},"Samsung Medical Center","RECRUITING","Seoul","South Korea",{"type":58,"coordinates":59},"Point",[60,61],126.9784,37.566,{"lat":61,"lon":60},[64],{"name":65,"role":48,"phone":19,"phoneExt":19,"email":19},"Seung Tae Kim, M.D., Ph.D.",{"type":67,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100613176",false,"NCT07263178","A Study of Second- and Later-line Palliative Chemotherapy in Patients With Metastatic Colorectal Cancer.","A Multi-center, Prospective, Observational Study to Assess the Treatment Patterns and Prognosis of Second and Later-line Palliative Chemotherapy in Patients With Metastatic Colorectal Cancer Who Failed First-line Palliative Chemotherapy","Inclusion Criteria:\n\n* Patients who have signed the informed consent after receiving information about the purpose and method of this study.\n* Patients with histologically and radiologically confirmed metastatic colorectal cancer (colorectal cancer) who have evaluable (measurable) lesions.\n* Patients scheduled to receive their first second-line palliative chemotherapy following failure of first-line palliative chemotherapy (including those who relapse during or within 6 months after completion of postoperative adjuvant therapy, necessitating palliative chemotherapy).\n* Patients who understand the research, are cooperative in the research process, and are deemed capable of participating until the completion date.\n\nExclusion Criteria:\n\n* Female patients who are pregnant, have childbearing potential, or are breastfeeding.\n* Has received an investigational product within 4 weeks from the study enrollment or has plans to participate in another clinical trial during the participation of this study.\n* Other subjects who are considered inappropriate to participate in this study by the judgment of the investigator.","ALL","19 Years",{"count":77,"type":78},1000,"ESTIMATED","OBSERVATIONAL","This study aims to comprehensively identify the various treatment patterns of second- or subsequent-line palliative chemotherapy used in patients with metastatic colorectal cancer who have experienced failure of first-line palliative chemotherapy and to evaluate the prognosis of each treatment.",[82],"Metastatic Colorectal Cancer",[84,82,85],"Palliative chemotherapy","Observation Study","2025-11-23",{"date":88,"type":89},"2025-12-04","ACTUAL",{"date":91,"type":89},"2025-11-07",{"date":93,"type":78},"2029-12",{"name":5,"class":6},1]